[
  {
    "ts": null,
    "headline": "Improved Pharma initiates research and development program",
    "summary": "SLNs are a type of nanocarrier used in drug delivery and vaccine development. They are composed of stabilized lipids and can encapsulate active pharmaceutical ingredients (APIs). This formulation approach can enable the transport of active molecules directly to target cells, protect encapsulated molecules from degradation, and enhance the solubility and bioavailability of poorly soluble drugs. The most well-known SLN formulations include the Moderna and Pfizer COVID-19 vaccines. However, there i",
    "url": "https://finnhub.io/api/news?id=b54e5f82adcfba70a29ca825210a6177c8e5730510ee554f7ec02c1f24b4305b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751389320,
      "headline": "Improved Pharma initiates research and development program",
      "id": 135698060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "SLNs are a type of nanocarrier used in drug delivery and vaccine development. They are composed of stabilized lipids and can encapsulate active pharmaceutical ingredients (APIs). This formulation approach can enable the transport of active molecules directly to target cells, protect encapsulated molecules from degradation, and enhance the solubility and bioavailability of poorly soluble drugs. The most well-known SLN formulations include the Moderna and Pfizer COVID-19 vaccines. However, there i",
      "url": "https://finnhub.io/api/news?id=b54e5f82adcfba70a29ca825210a6177c8e5730510ee554f7ec02c1f24b4305b"
    }
  },
  {
    "ts": null,
    "headline": "First-Half 2025 Stock Review And Second-Half Picks",
    "summary": "S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate market volatility.",
    "url": "https://finnhub.io/api/news?id=25ae8977030b098604071367398a9f6470c502adba3406fc606785f04c4091c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751386538,
      "headline": "First-Half 2025 Stock Review And Second-Half Picks",
      "id": 135697541,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156603572/image_2156603572.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate market volatility.",
      "url": "https://finnhub.io/api/news?id=25ae8977030b098604071367398a9f6470c502adba3406fc606785f04c4091c7"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Gains on Encouraging Flu Vaccine Data",
    "summary": "MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.",
    "url": "https://finnhub.io/api/news?id=b709db59e1575f6eaacb5ae0037cd6c103e19ff85d37e922ebec695396b4873e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751375820,
      "headline": "Moderna Stock Gains on Encouraging Flu Vaccine Data",
      "id": 135693362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.",
      "url": "https://finnhub.io/api/news?id=b709db59e1575f6eaacb5ae0037cd6c103e19ff85d37e922ebec695396b4873e"
    }
  },
  {
    "ts": null,
    "headline": "Former Moderna Chief Development Officer Melanie Ivarsson OBE Joins PhaseV's Scientific Advisory Board",
    "summary": "PhaseV, a leader in AI/ML-driven clinical development, today announced the appointment of Melanie Ivarsson OBE, PhD, to the company's scientific advisory board. A veteran drug development leader, Dr. Ivarsson most recently served as Senior Vice President and Chief Development Officer at Moderna, where she was honored as an Officer of the Order of the British Empire (OBE) for her leadership in the development of one of the first COVID-19 vaccinations.",
    "url": "https://finnhub.io/api/news?id=54e89d67006a27d8d33e4033b9d6e0e4af2ae6dd6ac91d82f3aa000e4a4ad2d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751373000,
      "headline": "Former Moderna Chief Development Officer Melanie Ivarsson OBE Joins PhaseV's Scientific Advisory Board",
      "id": 135694781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "PhaseV, a leader in AI/ML-driven clinical development, today announced the appointment of Melanie Ivarsson OBE, PhD, to the company's scientific advisory board. A veteran drug development leader, Dr. Ivarsson most recently served as Senior Vice President and Chief Development Officer at Moderna, where she was honored as an Officer of the Order of the British Empire (OBE) for her leadership in the development of one of the first COVID-19 vaccinations.",
      "url": "https://finnhub.io/api/news?id=54e89d67006a27d8d33e4033b9d6e0e4af2ae6dd6ac91d82f3aa000e4a4ad2d6"
    }
  }
]